X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Idronoxil
Therapeutic Area: Infections and Infectious Diseases Product Name: Veyonda
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2021
Details:
Part 1 of the NOXCOVID-1 trial involved 26 patients and was a dose-escalation arm testing the safety of increasing (400, 600, 800, 1200, 1800 mg) daily Veyonda dosages.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Idronoxil
Therapeutic Area: Infections and Infectious Diseases Product Name: Veyonda
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
The experimental anti-cancer drug, Veyonda®, joins a number of approved and experimental drugs with an anti-inflammatory action being tested globally for their ability to block rapid progression of COVID-19 disease from moderate to severe level.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Idronoxil
Therapeutic Area: Infections and Infectious Diseases Product Name: Veyonda
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2020
Details:
This action is designed to provide important safety data and proof-of-principle of using Veyonda®, as a potential treatment of the cytokine storm and septic shock that have emerged as major causes of morbidities and death in COVID-19 patients.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
